Business Context and Reporting Period
MedTech Acquisition Corporation (“MTAC”) filed this Form 8-K on June 12, 2023. The filing concerns MTAC’s proposed business combination with TriSalus Life Sciences, Inc. (“TriSalus”), under which MTAC Merger Sub, Inc. would merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary of MTAC. Following completion, MTAC is expected to be renamed TriSalus Life Sciences, Inc.
The filing furnishes a June 12, 2023 press release and social media posts regarding additional data presented by TriSalus at the 2023 American Society of Clinical Oncology Annual Meeting from its ongoing Pressure-Enabled Regional Immuno-Oncology-01 study in uveal melanoma with liver metastases.
Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash, liquidity, valuation or other quantitative financial metrics.
- The filing indicates that TriSalus continues to develop its TriNav Infusion System and SD-101 program, but it does not provide operating or sales figures.
- The referenced clinical-study data are not included in the provided filing text; therefore, the filing text does not provide a clear value for efficacy, tolerability or other clinical endpoints.
Material Changes Versus the Prior Comparable Period
- No period-over-period financial comparison is presented.
- Material transaction developments include amendments to the Merger Agreement dated April 4, 2023 and May 13, 2023, and the June 12, 2023 announcement of additional clinical data.
- MTAC stated that its Form S-4 registration statement, including the proxy statement/prospectus, had not yet been declared effective.
Guidance, Outlook, Risks and Unusual Items
Management did not provide financial guidance in the filing. Forward-looking statements address the potential tolerability and immunological effects of SD-101 delivered through TriNav, disease-control evidence, and continued program development.
Completion of the business combination remains subject to conditions including MTAC stockholder approval, satisfaction of minimum-cash requirements after redemptions, regulatory approvals and other closing conditions. Additional risks include failure to complete the transaction by the applicable deadline, termination of the Merger Agreement, Nasdaq listing risk, financing needs, reimbursement conditions, clinical-trial and regulatory risks, commercialization and market-size uncertainty, competition, and the ability to grow TriNav sales and fund SD-101 development.
The information under Item 7.01 and the related exhibits was furnished, not filed, for purposes of Section 18 of the Exchange Act. The filing also states that it is not an offer to sell securities or a solicitation of proxies.
Investor Verification Checklist
- Verify the current status and effectiveness of the Form S-4 and the date and outcome of the MTAC stockholder vote.
- Review the final Merger Agreement, amendments, closing conditions, minimum-cash requirement and redemption assumptions.
- Review the complete ASCO clinical data for the Pressure-Enabled Regional Immuno-Oncology-01 study, including patient population, endpoints, efficacy, safety and statistical limitations.
- Review TriSalus’s latest financial statements for revenue, cash burn, liquidity, debt, financing requirements and TriNav sales.
- Assess regulatory, reimbursement, clinical-development and commercialization risks for TriNav and SD-101.